Neoantigen Targeted Therapies Market Report 2026

Neoantigen Targeted Therapies Market Overview

• Neoantigen Targeted Therapies market size has reached to $4.71 billion in 2025 • Expected to grow to $21.52 billion in 2030 at a compound annual growth rate (CAGR) of 35.5% • Growth Driver: Surge Of Precision Oncology Propels Growth In The Neoantigen Targeted Therapies Market • Market Trend: Strategic Partnerships In Neoantigen Targeted Therapies To Personalize Cancer Treatment And Enhance Immunotherapy Effectiveness • North America was the largest region in 2025.

What Is Covered Under Neoantigen Targeted Therapies Market?

Neoantigen-targeted therapies are a type of precision medicine that concentrates on neoantigens in cancer cells. Neoantigens are distinct antigens that are derived from genetic abnormalities or modifications present in cancer cells. It is used to harness the body's immune system to recognize and attack cancer cells specifically by targeting these neoantigens. The main types of neoantigens targeted therapies are monotherapy and combination therapy. The term monotherapy refers to a medical approach to treating a problem or disease that uses only one medicine or therapy. The various immunotherapy types include DNA or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies that target various disease indications such as colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. The various routes of administration include intradermal, intravenous, and subcutaneous, and the various applications include medical research institutions, hospitals, clinics, and others.

What Is The Neoantigen Targeted Therapies Market Growth Forecast?

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $21.52 billion in 2030 at a compound annual growth rate (CAGR) of 35.5%. The growth in the forecast period can be attributed to rapid growth of personalized cancer therapies, increased investment in genomic sequencing, expanding clinical research collaborations, rising adoption of combination immunotherapies, growing demand for precision oncology solutions. Major trends in the forecast period include increasing adoption of personalized cancer vaccines, expansion of targeted immunotherapy research pipelines, rising clinical trials for neoantigen-based combination therapies, growing demand for early genetic profiling in oncology, surge in development of til-based therapeutic approaches.

Global Neoantigen Targeted Therapies Market Segmentation

1) By Type: Monotherapy, Combination Therapy 2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies 3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer 4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous 5) By Application: Medical Research Institution, Hospitals and Clinics, Other Applications Subsegments: 1) By Monotherapy: Individual Neoantigen-Targeted Treatments 2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

What Is The Driver Of The Neoantigen Targeted Therapies Market?

The rising precision oncology is expected to propel the growth of the neoantigen targeted therapies market going forward. Precision oncology is an approach to cancer treatment that utilizes detailed genetic and molecular information about a patient's tumor to guide the selection of targeted therapies. Precision oncology uses neoantigen-targeted therapies by leveraging advanced genomic analysis to identify unique neoantigens expressed by an individual's cancer cells. The utilization of neoantigen-targeted therapies in precision oncology reflects a strategy to address the specific genetic makeup of each patient's tumor, offering a more personalized and effective treatment option. For instance, in March 2024, according to the Precision Oncology Clinical Trials & Statistics 2024 report published by Novotech, an Australia-based full-service clinical contract research organization involved in the development of innovative therapeutics across all phases, by November 2023, twelve treatments had received FDA approval for specific biomarker-selected indications, with six of these also included in the NCCN guidelines. By the year's end, 43% of the 217 FDA-approved oncology therapies were classified as precision oncology, and 78 of these therapies featured DNA or NGS-detectable biomarkers, highlighting the growing prominence of biomarker-driven treatments in cancer care. Therefore, rising precision oncology is driving the growth of the neoantigen-targeted therapies market.

Key Players In The Global Neoantigen Targeted Therapies Market

Major companies operating in the neoantigen targeted therapies market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Kite Pharma Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Global Neoantigen Targeted Therapies Market Trends and Insights

Major companies operating in the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs to overcome the challenges of existing immunotherapy in the treatment of solid tumors. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in April 2023, Moderna, Inc., a US-based pharmaceutical and biotechnology company collaborated with Merck & Co., Inc. a US-based pharmaceutical company that launched mRNA-4157 (V940). It is an investigational individualized neoantigen therapy (INT) designed to generate a tailored antitumor immune response based on the unique mutational signature of a patient's tumor. mRNA-4157 (V940) works by encoding up to 34 neoantigens to stimulate T cell responses, enhancing the body’s ability to target and destroy tumor cells when combined with Merck’s immunotherapy KEYTRUDA. This combination aims to improve recurrence-free survival in patients with high-risk resected melanoma.

What Are Latest Mergers And Acquisitions In The Neoantigen Targeted Therapies Market?

In January 2023, AstraZeneca plc, a UK-based pharmaceutical industry company acquired Neogene Therapeutics Inc. for $200 million. This acquisition aims to bolster AstraZeneca’s oncology portfolio, focusing on the development of transformative T-cell receptor (TCR) therapies targeting neoantigens in solid tumors. Neogene's expertise in next-generation TCR-T therapies is expected to complement AstraZeneca's existing capabilities in the oncology space, enabling the company to further its advancements in cancer treatments. Neogene Therapeutics Inc. is a US-based biotechnology company that provides neoantigen-targeted therapies.

Regional Outlook

North America was the largest region in the neoantigen targeted therapies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neoantigen Targeted Therapies Market Report 2026?

The neoantigen targeted therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.